New Alzheimer’s Drug “EmestEDASTAT” Shows Promise in Early Trials
Sydney, Australia – A new Alzheimer’s drug developed by Australian biotechnology company Actinogen Medical is generating excitement in the medical community. Dubbed “xanamem” and now officially “EmestEDASTAT,” the drug is currently undergoing safety and activity testing on 100 volunteers, with interim results anticipated in early 2026.
A Decade in the Making
Actinogen has dedicated over ten years to developing this novel treatment. The active substance was initially discovered by researchers at the university of Edinburgh and shows potential benefits beyond Alzheimer’s, possibly extending to other neurological conditions like depression. Actinogen CEO steven Gourlay boldly calls the medicine a “holy grail” in the fight against Alzheimer’s, with trials currently underway at 35 centers across Australia and the United States.A Novel Approach: Targeting stress Hormones
Unlike many existing Alzheimer’s treatments that focus on reducing amyloid plaques (protein buildup) in the brain, EmestEDASTAT takes a different tack. It targets cortisol, the brain’s primary stress hormone. this innovative mechanism has garnered praise from experts like Christoph Kleinschnitz, Director of Neurology at Essen University Hospital, who described the approach as “exciting.” Kleinschnitz noted that Alzheimer’s patients often exhibit elevated cortisol levels, suggesting a link between stress and the disease’s progression.
